Theoretical Clinical Utility of Advanced Practice Provider Use of an Artificial Intelligence Radiomics-based Tool for Pulmonary Nodule Evaluation and Management.

Roger Y Kim^1,2, Annika Rings³, Lyndsey C Pickup³, Omar Ibrahim⁴, Anil Vachani^5,6

¹Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Pennsylvania, Philadelphia, PA.

²Penn Center for Cancer Care Innovation at the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

³Optellum, Ltd., Oxford, United Kingdom.

⁴Division of Pulmonary, Critical Care, and Sleep Medicine, University of Connecticut School of Medicine, Farmington, CT.

⁵Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New York University, New York, NY.

⁶Veterans Affairs New York Harbor Healthcare System, New York, NY.

PubMed PMC DOI PDF

Abstract

BACKGROUND: As integral members of pulmonary nodule (PN) programs, advanced practice providers (APPs) routinely evaluate PN cancer risk and make management recommendations. It is unknown whether an artificial intelligence (AI) tool impacts APP PN assessment and decision-making. RESEARCH QUESTION: What is the theoretical effect of APP use of a commercially available AI radiomics-based computer-aid…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.